These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34076966)

  • 21. Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer.
    Noro R; Yoshimura A; Yamamoto K; Miyanaga A; Mizutani H; Minegishi Y; Seike M; Kubota K; Kosaihira S; Hino M; Ando M; Nomura K; Okano T; Kobayashi K; Uematsu K; Gemma A;
    Anticancer Res; 2013 Mar; 33(3):1117-23. PubMed ID: 23482789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
    Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.
    Igawa S; Otani S; Ryuge S; Fukui T; Nakahara Y; Hiyoshi Y; Ishihara M; Kusuhara S; Harada S; Mitsufuji H; Kubota M; Sasaki J; Masuda N
    Invest New Drugs; 2017 Oct; 35(5):642-648. PubMed ID: 28631097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
    Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S;
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
    Spigel DR; Dowlati A; Chen Y; Navarro A; Yang JC; Stojanovic G; Jove M; Rich P; Andric ZG; Wu YL; Rudin CM; Chen H; Zhang L; Yeung S; Benzaghou F; Paz-Ares L; Bunn PA;
    J Clin Oncol; 2024 Jul; 42(19):2317-2326. PubMed ID: 38648575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
    Sekine I; Okamoto H; Horai T; Nakagawa K; Ohmatsu H; Yokoyama A; Katakami N; Shibuya M; Saijo N; Fukuoka M
    Clin Lung Cancer; 2014 Mar; 15(2):96-102. PubMed ID: 24361248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
    Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
    Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
    Zatloukal P; Cardenal F; Szczesna A; Gorbunova V; Moiseyenko V; Zhang X; Cisar L; Soria JC; Domine M; Thomas M
    Ann Oncol; 2010 Sep; 21(9):1810-1816. PubMed ID: 20231298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
    Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
    Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
    J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
    Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. S-1 Maintenance Therapy in Extensive Stage Small-Cell Lung Cancer-A Randomized Clinical Study.
    Nie K; Guo X; You Y; Zhuang X; Zhang C; Ji Y
    Cancer Control; 2020; 27(2):1073274820932004. PubMed ID: 32551853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
    Owonikoko TK; Aisner J; Wang XV; Dahlberg SE; Rubin EH; Ramalingam SS; Gounder M; Rausch PG; Axelrod RS; Schiller JH
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):171-80. PubMed ID: 24288121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of the Efficacy of Irinotecan in the Second-line Treatment of Refractory and Relapsed Small Cell Lung Cancer].
    Xing H; Zhang J; Ge F; Yu X; Bian H; Zhang F; Fang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):167-172. PubMed ID: 33819966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
    Ready NE; Pang HH; Gu L; Otterson GA; Thomas SP; Miller AA; Baggstrom M; Masters GA; Graziano SL; Crawford J; Bogart J; Vokes EE
    J Clin Oncol; 2015 May; 33(15):1660-5. PubMed ID: 25732163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic factors and response of chemotherapy including amrubicin in small cell lung cancer patients].
    Wang Y; Liu L; Wu M; Zhong J; Liu X; An T; Zhao J; Duan J; Wang Z; Zhou M; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2015 Apr; 38(4):261-6. PubMed ID: 26268231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
    Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
    Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
    Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
    Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
    Schneider BJ; Kalemkerian GP; Ramnath N; Kraut MJ; Wozniak AJ; Worden FP; Ruckdeschel JC; Zhang X; Chen W; Gadgeel SM
    Clin Lung Cancer; 2010 Jul; 11(4):223-7. PubMed ID: 20630823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.